The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Long-term follow-up of SEQUOIA: zanubrutinib vs bendamustine and rituximab in treatment-naive CLL
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, Alfred Hospital and Monash University, Melbourne, Australia, discusses long-term follow-up of the SEQUOIA study (NCT03336333), investigating zanubrutinib versus bendamustine and rituximab in treatment-naive chronic lymphocytic leukemia (CLL). Prof. Tam highlights findings from arm A and arm B of the trial, as well as arm C, which explored responses in patients with 17P deletion. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
